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ischemia (CLI) have not been previously reported in Taiwan. This study assessed the safety,
feasibility, and patient-oriented outcomes for CLI patients after EVI.
Methods: From June 2005 to December 2011, 270 patients underwent EVI for CLI of 333 limbs.
Primary patency (PP), assisted primary patency (AP), limb salvage, sustained clinical success
(SCS), secondary SCS (SSCS), and survival were assessed using Kaplan-Meier analysis.
Results: The procedural success rate was 89%, and the periprocedural mortality and major
complication rates within 30 days were 0.6% and 6.9%, respectively. During the mean follow-
up time of 27  20 months (1e77), 64 patients died and 25 legs required major amputation.
Eighty-one percent of the patients with tissue loss had wound healing at 6 months and 75%
of the patients were ambulatory, with or without assisting devices, at 1 year. The overallhave no conflicts of interest relevant to this article.
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Endovascular interventions for critical limb ischemia 689survival and limb salvage rates at 3 years were 70% and 90%, respectively. The PP and AP at 1
and 3 years were 58% and 37% and 79% and 61%, respectively. The SCS and SSCS were 65% and
46% and 80% and 64% at 1 and 3 years, respectively.
Conclusion: In Taiwan, EVI was a safe and feasible procedure for CLI patients, with a high pro-
cedural success rate and lower complication rate. Sustained limb salvage and clinical success
can be afforded with an active surveillance program and prompt intervention during midterm
follow-up.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Critical limb ischemia (CLI) is the most severe form of
peripheral artery disease, defined as chronic ischemic rest
pain, ischemic ulcers, and gangrene attributable to objec-
tively proven arterial occlusive disease.1 Without timely
revascularization, CLI carries a 25% risk of mortality and
another 25% risk of amputation over the next year.2
Revascularization therapy, either endovascular inter-
vention (EVI) or bypass surgery, is indicated for patients
with CLI. Remarkable technological advances in the past
decade, along with patient preferences, have changed
revascularization strategies from traditional bypass sur-
gery to less invasive EVI.3e5 EVI offers several advantages
over surgical bypass for selected lesions.6 Performed under
local anesthesia, it enables treatment of patients who are
at high risk for general anesthesia. Many physicians rec-
ommend EVI as the first-line therapy in patients with
chronic lower limb ischemia, because of its low mortality,
and acceptable midterm assisted patency and limb salvage
rates.7e9 In Taiwan, the midterm outcomes of EVI for CLI
patients were not clear; with this study, we evaluated the
safety, feasibility, and midterm outcomes of EVI for
patients with CLI.
Materials and methods
Study population
From June 2005 to December 2011, 326 consecutive
patients with 403 affected legs were referred to this insti-
tution for EVI, because of symptomatic low extremity
arterial disease. A total of 270 patients presented with 333
limbs affected with CLI. The definition of CLI, derived from
the current consensus of clinical presentation, consists of
rest pains, ulcers, or gangrene. The exclusion criteria for
EVI included patients with: (1) infrarenal aortic occlusion;
(2) no target vessel below the knee; (3) end-stage renal
disease (ESRD) without regular hemodialysis; (4) contra-
indications for aspirin or clopidogrel; (5) acute limb ische-
mia requiring emergent revascularization; (6) symptoms of
intermittent claudication; (7) overwhelming infection
threatening the patient’s life; and (8) procedure refusal.
Pre-interventional study included a clinical examina-
tion, hemodynamic evaluation (ankle or toe pressure,
pulse volume recording, duplex scanning), and anatomic
assessment, including computed tomographic angiography,
magnetic resonance angiography, or diagnostic angiog-
raphy. Decisions on the revascularization strategy were
based on the clinical examination, anatomic evaluation,and the patient’s comorbidities. Usually, less invasive EVI
was the first-choice revascularization strategy (including
the tibial arteries) and open bypass surgery served as a
back-up option. Toe pressures, pulse volume recording,
and Doppler waveform patterns were performed to meas-
ure the hemodynamic changes in patients with falsely
elevated ankle brachial index (ABI) values. A single-level
intervention was defined as EVI for isolated aortoiliac,
femoropopliteal, or below-the-knee (BTK) lesions. A mul-
tilevel intervention was defined as EVI in more than one
area.
The diagnosis of diabetes mellitus (DM) was determined
from the hospital records and confirmed by the patient’s
use of oral hypoglycemic agents or insulin. Chronic renal
failure was defined as a serum creatinine level of >1.5 mg/
dL, or if the patients received regular dialysis due to ESRD.
History of coronary artery disease was defined as a diam-
eter stenosis of >50% in one of the three main coronary
arteries, or prior revascularization by percutaneous coro-
nary intervention or bypass grafting. Hypertension and
congestive heart failure were documented by medical
records and confirmed by use of the appropriate medi-
cations. For each patient, we recorded demographic and
interventional data, including clinical presentation
according to the Rutherford classification (RC),10 lesion
anatomy based on the Trans-Atlantic Intersociety Con-
sensus (TASC) I and II system, and follow-up ABIs, toe
pressures, and duplex ultrasounds.
Interventions
The interventional procedure was usually conducted using
either the antegrade or crossover approach, but also
through multiple access sites (brachial or pedal puncture)
for complex cases. All patients received 100 mg aspirin and
75 mg clopidogrel per day for 4 days before the EVI. Aspirin
was administered continuously after the intervention.
Clopidogrel was used for 3 months if the self-expandable
nitinol or balloon-expandable bare-metal stent was
implanted, or for 12 months if the drug-eluting stent was
used. Unfractionated heparin (5000e10,000 units) was
administered during the procedure, to maintain an acti-
vated coagulation time of around 250 seconds. Lesions were
crossed intraluminally or subintimally with hydrophilic
(0.014-, 0.018-, 0.035-inch) or platinum-tipped (0.014-,
0.018-, 0.035-inch) guidewires. The routine stenting strat-
egy in iliac intervention was performed after reimburse-
ment by National Health Insurance, and provisional stenting
was used in infrainguinal management. Additional proce-
dures, including such devices as cutting balloons, cry-
oballoons (cryoplasty), excimer lasers (atherectomy), or
Table 1 Baseline demographics.
Patient numbers: n Z 270
Sex: male, 132 (49%)
Age: 71  11 y old
Underlying medical comorbidities
Diabetes mellitus: 222 (82%)
Hypertension: 230 (85%)
Chronic renal failure: 146 (54%)
Chronic kidney disease: 47 (17%)
Dialysis dependence: 99 (37%)
Hyperlipidemia: 145 (54%)
Coronary artery disease: 111 (41%)
Smoking: 95 (35%)
Cerebrovascular accident: 69 (26%)
Congestive heart failure: 40 (15%)
PIII risk score
Low (0e3): 83 (31%)
Medium (4e7): 111 (41%)
High ( 8): 76 (28%)
Treated extremities: n Z 333
Rest pain: 85 (25%)
Ulcer: 169 (51%)
Gangrene: 79 (24%)
Target extremity ABI: 0.48  0.16
ABI Z ankle brachial index; ESRD Z end-stage renal disease.
690 H.-L. Huang et al.drug-eluting balloons, were performed at the discretion of
the operator to improve the immediate technical success.
Definitions
Technical success was defined as successful access and
deployment of the device and 30% residual diameter
stenosis by quantitative angiography, with evidence of at
least one tibial artery to the foot. Procedural success was
defined as technical success without periprocedural com-
plications. Immediate hemodynamic success was defined as
ABI improvement of 0.15, as compared to the baseline
data. Periprocedural major complications were defined as
death, myocardial infarction, stroke, unplanned bypass,
contrast-induced acute kidney injury requiring dialysis,
compartment syndrome requiring a fasciotomy, and groin
complications, such as pseudoaneurysm or arteriovenous
fistula sealed by ultrasound-guided manual compression or
surgical repair.
Minor complications were defined as vessel perforation
caused by the guidewire, and access site hematoma with-
out blood transfusion (a fall in hemoglobin <2 g/dL). Pri-
mary patency (PP) was defined as persistent patency
without recurrent symptoms in the face of worsening ABIs
and a dampened Doppler waveform pattern due to recur-
rent disease. Assisted primary patency (AP) was achieved
by reintervention for restenosis, reocclusion, or a new
lesion on the treated leg. Sustained clinical success (SCS)
was defined as continuous clinical improvement without
the need for target extremity revascularization, recurrent
ulceration, or major amputation. Clinical improvement was
defined as an RC score improvement of 2þ; an ABI
increase of at least 0.15, and wound healing in 4 months
of index intervention for patients with tissue loss. Secon-
dary SCS (SSCS) was defined as clinical improvement with
target extremity revascularization and without major
amputation. Major amputation was defined as limb loss
above or below the knee. Minor amputation included
transmetatarsal or toe amputation. The protocol was
reviewed and approved by the institutional review board,
and written informed consent forms were obtained for all
patients enrolled in this study.
Patient follow-up
After being discharged from the hospital, all patients with
successful procedures were followed up at an outpatient
clinic. Patients with tissue loss underwent wound debride-
ment, free flap transplant, and hyperbaric oxygen therapy
by a plastic surgeon or orthopedist, until their wounds
healed. Clinical examination and duplex ultrasounds were
performed at 1 week, 1 month, and 3 months after the
index procedures, and every 3 months thereafter. Repeat
interventions were conducted if recurrent symptoms, sig-
nificant vessel stenosis ( 70%) with dampened Doppler
waveform patterns by duplex ultrasound, and an ABI
decrease of 0.2, were observed. Major events (mortality,
limb amputation, PP failure, and failure of SCS) were
documented at the time of hospital discharge, or during the
3-month follow-up office visits. In the event office follow-
up was not feasible, telephone interviews, data obtainedfrom medical records, local electronic medical databases,
and referring physicians were used as alternate data
sources.
Analysis and statistics
Categorical variables were reported as counts and percen-
tages, and continuous variables were reported as the
mean  standard deviation. Continuous variables were
analyzed using t tests and c2 tests were used to compare
the wound healing rate and ambulatory status before and
after the EVI. PP, AP, limb salvage, SCS, SSCS, and survival
were assessed using Kaplan-Meier analysis. For the survival
analyses, a census of the surviving patients was done on the
date of last clinical contact. Eighteen patients were
excluded from the study because they did not keep their
first follow-up appointment 1 month after the index pro-
cedure. All analyses were performed using Stata 10 (Sta-
taCorp, College Station, TX, USA). Statistical significance
was set at p < 0.05.
Results
Baseline demographics (Table 1)
Our study population consisted of a total of 270 consec-
utive patients with 333 treated limbs. Forty-nine percent
were male patients, with a mean age of 71  11 years. Most
of the study patients had multiple comorbidities. Using PIII
CLI risk scoring,11 69% of the study patients were medium
to high risk for bypass surgery. The most frequent
Table 3 Procedural results and complications.
Treated limbs: n Z 333
Procedure success rate: 314 limbs (94%)
Failed treated limbs: 19
BK amputations: 3
Bypass surgery: 7
Minor amputation: 1
Conservative: 4
Second attempt of intervention: 4
ABI after intervention: 0.87  0.16
Stent implantation in 177 legs intervention (53%)
Iliac artery: 59 stents in 47 lesions
FP artery: 178 stents in 115 lesions
BTK artery: 74 stents in 52 lesions
Additional devices:
Cutting balloon: 44 Excimer laser (atherectomy): 23
Reentry device: 1
Drug-eluting balloon: 2 Cryoballoon (cryoplasty): 3
Covered stent: 1
Death: 0
Vessel perforation: 23
Wire perforation: 22, stent graft: 1
Acute vessel closure requiring stent implantation: 3
Distal embolization: 13
Catheter aspiration: 11
IA urokinase: 2
BTK Z below the knee; FP Z femoropopliteal; IA Z intra-
arterial.
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resting pain (25%) and foot gangrene (24%). The mean ABIs
of the target extremity at initial presentation were
0.48  0.16.
Lesion morphology of the treated limbs (Table 2)
The detailed lesion morphology of the treated limbs is lis-
ted in Table 2. Single-level endovascular treatment (EVT)
was performed on 170 limbs (51%) and multilevel EVT on the
remaining treated limbs. Thirty limbs had undergone
previous bypass surgery, and eight had undergone failed
EVIs at other institutions. A total of 680 lesions underwent
EVT in 333 limbs and totally occluded arteries were
observed in 252 (37%) vessel segments. Most of the infra-
popliteal lesions belonged to TASC D diffuse diseased ves-
sels. The mean lesion length of aortoiliac, femoropopliteal,
and BTK vessel segments was 6.24  3.29 cm,
11.92  7.68 cm, and 13.47  7.21 cm, respectively.
Procedural results (Table 3)
The overall technical and procedural success rates were 94%
and 89%, respectively. There were 19 failures of the initial
EVI; of these, seven limbs underwent bypass surgery, three
immediate below-knee amputations, oneminor amputation,
four conservative treatments, and four second attempts at
EVI. Of the four limbs undergoing a second EVI, three were
successfully revascularized and one ultimately went into
below-knee amputation. Patients with successful EVIs had
significant, immediate hemodynamic improvement, with
the ABIs increasing from 0.48  0.16 to 0.87  0.16
(p < 0.001). Subsidence of intractable pain was observed in
95% of the successfully revascularized limbs. All lesions wereTable 2 Baseline lesion characteristics of treated limbs.
Treated limbs: n Z 333
Previous bypass surgery: 30, previous EVI: 8
Single-level lesion: 170 (51%)
Iliac artery: 32 (9.6%)
FP artery: 52 (15.6%)
BTK artery: 85 (25.5%)
Multilevel lesions: 164 (49%)
Iliac and FP arteries: 8 (2.4%)
FP and BTK arteries: 146 (43.8%)
Iliac and FP and BTK arteries: 10 (3%)
Lesion characteristics:
Aortoiliac
n Z 54
Stenosis: 45
Occlusion: 9
TASC
A 5
B 22
C 17
D 10
Lesion length: 6.24  3.29 cm
BTK Z below-the-knee; EVI Z endovascular intervention; FP Z femotreated by angioplasty, but 53% of the limbs required stent
implantation to optimize the angiographic results. Other
additional devices were used in 64 legs (19%) for debulking,
or where the area for the stent was unsuitable.FP BTK
n Z 217 n Z 409
144 239
73 170
16 8
108 49
58 65
35 287
11.92  7.68 cm 13.47  7.21 cm
ropopliteal; TASC Z Trans-Atlantic Intersociety Consensus.
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vessel perforations, 22 were caused by guidewire manipu-
lation, but there were no sequelae after prolonged balloon
inflation. One popliteal perforation during laser angioplasty
required a stent-graft implantation. Three legs underwent
immediate stent implantation, owing to acute vessel clo-
sure. Distal embolization was observed in 13 limbs (3.9%)
and was successfully treated by catheter aspiration in 11,
with adjuvant intra-arterial urokinase used in the other two
limbs.
In-hospital and 30-day outcomes (Table 4)
Two patients died during hospitalization, one related to
acute myocardial infarction and the other from decom-
pensated heart failure. Three patients required urgent
dialysis due to contrast-induced acute kidney injury and
three suffered cerebrovascular events. Emergent surgery,
with above-knee amputation, occurred in one patient, due
to acute arterial thrombosis caused by procedure failure.
Of the five patients affected with subacute arterial
thrombosis within 30 days, four underwent successful
reinterventions and one ultimately required an above-knee
amputation. Of the eight groin complications, four cases of
retroperitoneal bleeding needed blood transfusions, three
pseudoaneurysms underwent ultrasound-guided manual
compression, and one embolization of a collagen clot after
dislodgement of the closure device required surgical repair.
The mortality and major complication rates within 30 days
were 0.6% and 6.9%, respectively. The ABIs 1 month after
EVI increased to 0.92  0.17.
Follow-up results
Of the 270 participants with 333 limbs, 14 patients were
excluded, because of failed procedures (94% success rate),
leaving a total of 256 patients (314 limbs) in the study.
Eighteen patients with 20 limbs were lost (93% follow-up
rate) during a mean follow-up time of 27  20 months
(range Z 1e77), meanwhile, 64 patients died, 40 (62%) by
noncardiovascular causes and 24 (38%) by cardiovascularTable 4 In hospital and 30-day outcomes.
Deaths: 2
Myocardial infarction: 1
CVA/SDH: 3
Contrast nephropathy requiring hemodialysis: 3
Emergent surgery: 1
Subacute arterial thrombosis: 5
Groin complications: 8
Retroperitoneal bleeding: 4
Pseudoaneurysm: 3
Collagen clot embolization: 1
Periprocedural mortality: 2 (0.6%)
Periprocedural major complications: 23 (6.9%)
ABI 1 mo after intervention: 0.92  0.17
ABI Z ankle brachial index; CVA Z cerebrovascular accident;
SDH Z subdural hematoma.causes. Of the 294 limbs monitored during the follow-up
period, 25 required major amputations and 34 underwent
minor amputations. Because of the failure of SCS, 74 repeat
interventions were performed. Within 4 months, wound
healing occurred in 67% of the patients with tissue loss and
improved to 81% at 6 months. Patients with an RC 5 score
had faster wound healing than patients with an RC 6 score
at either 4 months (74% vs. 48%, p < 0.001) or 6 months (86%
vs. 70%, p Z 0.003) (Fig. 1). Following successful EVIs, 132
(52%) patients returned to independent ambulation, 44
(19%) were ambulatory with assistive devices, and 36 (15%)
were wheelchair-bound. The EVI significantly improved the
ambulatory status of CLI patients at 1 year as compared to
their preoperative status (p < 0.001) (Fig. 2). EVI was also
performed in 17 bed-ridden patients; of these, four
returned to being wheelchair-bound, 12 remained bed-
ridden, and one was lost to follow-up. The 1-year survival
rate for bed-ridden patients was only 30.7%. The overall
survival rates at 1 and 3 years were 88% and 70%, respec-
tively (Fig. 3). The rates for being free from major ampu-
tation and any amputation were 90% and 78%, respectively,
at 1 year and were sustained up to 3 years (Fig. 4). The PP
and AP at 1 and 3 years were 58% and 37% and 79% and 61%,
respectively (Fig. 5). The SCS and SSCS rates at 1 and 3
years were 65% and 46% and 80% and 64%, respectively
(Fig. 6).
Discussion
This study is the first to report midterm outcomes using EVI
in the management of CLI in Taiwan. It demonstrated that
EVI was a safe and feasible procedure for CLI patients, with
high procedural success and lower complication rates.
Maintaining limb salvage and SCS can be accomplished
during follow-up.
Traditionally, patients in Taiwan with CLI usually
underwent primary amputation or bypass surgery. Tseng
et al reported that DM accounted for 37% of the low
extremity amputations.12 Over the past decade, the most
significant change in CLI treatment has been the shift from
bypass surgery to less invasive EVI. The main advantages of
EVI are low complication rates, ranging from 0.5% to 4.0%,Figure 1 Change in wound healing rate between Rutherford
classification (RC) 5 and RC 6 at 4 months, p < 0.001 and
between RC 5 and RC 6 at 6 months, p Z 0.003.
Figure 2 Change in ambulatory status before and after the
intervention, p < 0.001. AIZ ambulatory independently; AAZ
ambulatory with assistive device; W Z wheelchair-bound.
Figure 4 The KaplaneMeier curve for patients free from
major or minor amputation.
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approaching 90%, and acceptable short-term clinical out-
comes.2 The BASIL trial demonstrated that the rates of
amputation-free survival are similar for bypass surgery and
balloon angioplasty for at least 2 years after the proce-
dure.13 In our study, the overall technical success rate (94%)
was comparable to previous reports14e16 and may be rela-
ted to recent advances in endovascular devices and tech-
niques. The mortality and major complication rates within
30 days were 0.6% and 6.9%, respectively, even though most
of the study patients were elderly with multiple comor-
bidities or at high surgical risk. Our data demonstrate that
EVI is safe and feasible for CLI patients in Taiwan. Mortality
was rare and complications were low when the procedure
was performed by a skilled interventionist.Patency, clinical success, and limb salvage
When compared with bypass surgery, EVI has been criti-
cized for its lower PP rates and higher reintervention rates.
The 3-year PP in this series was 37%, similar to previous
reports.9,17 The high restenosis rates reflect advancedFigure 3 The overall survival of 256 patients.arterial disease in Taiwanese patients with CLI. The AP and
SSCS rates at 3 years were 61% and 64%, respectively, which
indicated that repeat EVI was required to maintain the
midterm outcomes in these patients.
Our study showed that the limb salvage rate at 3 years
was 90%, similar to the results of previous reports.10,18,19 All
amputations were performed in the 1st year, and 34 limbs
originally designated for limb loss only required minor
amputations. Thus, the limb salvage rate did not change
significantly after the 2nd year. Intensive surveillance, fol-
lowed by prompt assisted intervention, also prevented
recurrent major tissue loss and supported the high limb
salvage rate.Survival
Without revascularization, 25% of the patients with CLI will
die within 12 months and 32% within 24 months.1 Conrad
et al stated that there is a 12% annual death rate and 39% 5-
year survival rate in CLI patients after EVI.17 In Taiwan,
information is scarce about the long-term survival of CLI
patients after EVI. The 3-year survival rate (70%) was sim-
ilar to previous reports,8,18 and our results demonstratedFigure 5 The Kaplan-Meier curve for primary patency and
assisted primary patency.
Figure 6 The Kaplan-Meier curve for sustained clinical suc-
cess and secondary sustained clinical success.
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CLI was higher. Interestingly, most of the patients in this
series died from non-cardiovascular causes (62%), mainly
from sepsis secondary to other sources, not a lower limb
infection, followed by malignancy. This result reflects the
multiple comorbidities and immunocompromised states in
this patient group.
Wound healing
Without revascularization, ulcer healing was slow, with only
25% healed at 6 months and slightly more than 50% at 1
year.20 In our results, wound healing occurred in 67% of the
patients at 4 months (time frame for wound healing
reported by Nicoloff et al).21 Because of greater tissue loss
at initial presentation, 33% of the study patients required a
longer duration for wound closure. A lack of awareness of
disease severity in Taiwan, and delays in the referrals that
would have enabled early revascularization, also made
wound care more difficult.
Ambulation
Functional capacity and independent living status remain a
pertinent issue for the management of patients with CLI,
because ambulation is an independent factor for long-term
survival.22,23 In our series, we found significant improve-
ment in ambulatory status after successful revasculariza-
tion. Resolution of resting pain, and closure of non-healing
ulcers, helps CLI patients to be ambulatory or live
independently.
There are some limitations in our study. First, it was a
single-center, observational study from a prospective
database. Treatment allocation was made at the dis-
cretion of the operator and the patient’s policy of reim-
bursement. Second, the fact that all of the patients were
treated at a single center opens up the possibility of
referral/selection bias based on the current practice of
the group. Third, no follow-up questionnaire analysis was
conducted to assess the quality of life, as perceived by
the patients. Moreover, the baseline clinicalcharacteristics of the studied populations varied widely,
and thus, drawing direct comparisons between studies
may be difficult.
In conclusion, EVI was a safe and feasible procedure for
patients with CLI in Taiwan. It offered a high procedural
success rate and lower complication rate. An active sur-
veillance program, multidiscipline team care, and prompt
assisted intervention, maintained the limb salvage and
clinical success during the midterm follow-up.References
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